Zacks Investment Research
16 Jun 2026, 17:46 UTC · 3h ago
InspireMD Posts Positive CGUARDIANS II Data for CGuard Prime TCAR
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
16 Jun 2026, 17:46 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
InspireMD's CGUARDIANS II clinical trial met key safety and efficacy endpoints, reporting a 100% acute device success rate and no deaths, strokes, or myocardial infarctions within 30 days. — Positive clinical trial data for a medical device is a primary driver for valuation and regulatory success in biotech/med-tech.
+0.60The company anticipates potential FDA approval of the CGuard Prime 80 cm implant in the second half of 2026. — FDA approval provides a clear timeline for potential commercialization and revenue growth.
+0.50FDA approval of the device would allow InspireMD to access a market of more than 35,000 TCAR procedures performed annually in the United States. — Quantifying the addressable market expansion suggests a significant potential increase in the company's revenue ceiling.
+0.40Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company announced positive clinical trial results for its CGuard Prime implant, potentially expanding its addressable market and long-term growth prospects.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
PRNewsWire
42m ago
